Search

Your search keyword '"Younes, Ramy"' showing total 251 results

Search Constraints

Start Over You searched for: Author "Younes, Ramy" Remove constraint Author: "Younes, Ramy"
251 results on '"Younes, Ramy"'

Search Results

1. An unbiased ranking of murine dietary models based on their proximity to human metabolic dysfunction-associated steatotic liver disease (MASLD)

3. Impact of PNPLA3 rs738409 Polymorphism on the Development of Liver-Related Events in Patients With Nonalcoholic Fatty Liver Disease

4. Validation of the Blood Test MACK-3 for the Noninvasive Diagnosis of Fibrotic Nonalcoholic Steatohepatitis: An International Study With 1924 Patients

5. Performance of non-invasive tests and histology for the prediction of clinical outcomes in patients with non-alcoholic fatty liver disease: an individual participant data meta-analysis

6. A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis

7. GS-006 Glucagon and GLP-1 receptor dual agonist survodutide improved liver histology in people with MASH and fibrosis: Results from a randomized, double-blind, placebo-controlled phase 2 trial

9. OS-119 Survodutide (BI 456906), a glucagon receptor/glucagon-like peptide-1 receptor (GCGR/GLP-1R) dual agonist, in people with compensated and decompensated cirrhosis: a multinational, open-label, phase 1 trial

12. Increased serum miR-193a-5p during non-alcoholic fatty liver disease progression: Diagnostic and mechanistic relevance

14. SURVODUTIDE REDUCES LIVER FAT CONTENT, TRANSAMINASES, AND FIBROSIS MARKERS WITH GOOD SAFETY PROFILE IN PEOPLE WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH): AN INTERIM ANALYSIS OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 TRIAL

16. Monitoring Occurrence of Liver-Related Events and Survival by Transient Elastography in Patients With Nonalcoholic Fatty Liver Disease and Compensated Advanced Chronic Liver Disease

17. Serum ferritin levels can predict long-term outcomes in patients with metabolic dysfunction-associated steatotic liver disease

18. NASH limits anti-tumour surveillance in immunotherapy-treated HCC

20. Serum ferritin levels can predict long-term outcomes in patients with metabolic dysfunction-associated steatotic liver disease

25. Impact of PNPLA3 rs738409 polymorphism on the development of liver-related events in patients with non-alcoholic fatty liver disease

26. Noninvasive assessment of liver disease severity in patients with nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes

27. Machine learning algorithm improves the detection of NASH (NAS-based) and at-risk NASH: A development and validation study

28. Cross-Sectional and Longitudinal Performance of Non-Invasive Tests of Liver Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease

29. Validation of the blood test MACK-3 for the noninvasive diagnosis of fibrotic NASH: an international study with 1,924 patients

30. 241 - Glucagon and GLP-1 receptor dual agonist survodutide improved liver histology in people with MASH and fibrosis: Results from a randomized, double-blind, placebo-controlled phase 2 trial

31. Determinants of liver stiffness measurements in patients with NAFLD-an individual patient data meta-analysis

32. Diagnostic accuracy of non-invasive tests for fibrotic NASH-An individual participant data meta-analysis

33. Diagnostic accuracy of non-invasive tests for cirrhotic NASH-an individual participant data meta-analysis

34. Macrophage Scavenger Receptor 1 mediates lipid-induced inflammation in non-alcoholic fatty liver disease

35. Caucasian lean subjects with non-alcoholic fatty liver disease share long-term prognosis of non-lean: time for reappraisal of BMI-driven approach?

36. Global multi-stakeholder endorsement of the MAFLD definition

37. Global multi-stakeholder endorsement of the MAFLD definition

38. Increased serum miR-193a-5p during non-alcoholic fatty liver disease progression: Diagnostic and mechanistic relevance

39. Performance of non-invasive tests and histology for the prediction of clinical outcomes in patients with non-alcoholic fatty liver disease: an individual participant data meta-analysis

40. Long-term outcomes and predictive ability of non-invasive scoring systems in patients with non-alcoholic fatty liver disease

41. Sulfatase-2 from Cancer Associated Fibroblasts: An Environmental Target for Hepatocellular Carcinoma?

42. Redefinition of Fatty Liver Disease from NAFLD to MAFLD through the Lens of Drug Development and Regulatory Science

43. Long-term outcomes and predictive ability of non-invasive scoring systems in patients with non-alcoholic fatty liver disease

44. Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: A systematic review and meta-analysis

45. Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis

46. enDiagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis

47. Monitoring Occurrence of Liver-Related Events and Survival by Transient Elastography in Patients With Nonalcoholic Fatty Liver Disease and Compensated Advanced Chronic Liver Disease

48. Long-term outcomes and predictive ability of non-invasive scoring systems in patients with non-alcoholic fatty liver disease

49. Long-term outcomes and predictive ability of non-invasive scoring systems in patients with non-alcoholic fatty liver disease

50. Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis

Catalog

Books, media, physical & digital resources